Page last updated: 2024-12-06

fluchloralin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fluchloralin is a pre-emergence herbicide used to control annual grasses and broadleaf weeds in a variety of crops. It was first synthesized in the 1960s and its mode of action involves inhibiting root growth by disrupting microtubule formation in plant cells. Fluchloralin is readily absorbed by plants and has a relatively long persistence in soil. It is considered to be a moderately toxic compound to aquatic organisms and has been shown to have some negative effects on human health, including potential carcinogenicity. Fluchloralin has been widely used in agriculture, but its use has been restricted in some countries due to concerns about its environmental and health effects. Studies on fluchloralin focus on understanding its environmental fate and transport, its effects on non-target organisms, and the development of safer alternatives.'

fluchloralin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID36392
CHEMBL ID1256704
CHEBI ID81919
SCHEMBL ID54746
MeSH IDM0059277

Synonyms (54)

Synonym
benzenamine, n-(2-chloroethyl)-2,6-dinitro-n-propyl-4-(trifluoromethyl)-
fluchloralin
33245-39-5
basalin
bas 3921
bas 3922
p-toluidine, n-(2-chloroethyl)-2,6-dinitro-n-propyl-alpha,alpha,alpha-trifluoro-
einecs 251-426-0
bas 3924h
n-(2-chloroethyl)-n-propyl-2,6-dinitro-4-trifluoromethylaniline
epa pesticide chemical code 108701
n-propyl-n-(2-chloroethyl)-2,6-dinitro-4-trifluoromethylaniline
caswell no. 460b
n-(2-chloroethyl)-2,6-dinitro-n-propyl-4-(trifluoromethyl)aniline
fluchloralin [ansi:bsi:iso]
p-toluidine, n-(2-chloroethyl)-alpha,alpha,alpha-trifluoro-2,6-dinitro-n-propyl-
hsdb 3919
fluchloraline [iso-french]
brn 2778716
n-propyl-n-(2-chloroethyl)-alpha,alpha,alpha-trifluoro-2,6-dinitro-p-toluidine
bas 392 04 h
bas 392-h
n-(2-chloroethyl)-alpha,alpha,alpha-trifluoro-2,6-dinitro-n-propyl-p-toluidine
n-(2-chloroethyl)-2,6-dinitro-n-propyl-4-(trifluoromethyl)benzenamide
bas 3921h
n-(2-chloroethyl)-2,6-dinitro-n-propyl-4-(trifluoromethyl)benzenamine
bas 3920
C18730
dtxsid9032614 ,
tox21_301333
cas-33245-39-5
dtxcid7012614
NCGC00255196-01
chebi:81919 ,
CHEMBL1256704
98uif19ah9 ,
fluchloraline
unii-98uif19ah9
FT-0630569
AKOS015903552
SCHEMBL54746
n-(2-chloroethyl)-.alpha.,.alpha.,.alpha.-trifluoro-2,6-dinitro-n-propyl-p-toluidine
fluchloralin [iso]
bas-392h
fluchloralin [mi]
fluchloralin [hsdb]
basalin (basf)
bas 3921 h
n-propyl-n-(2-chloroethyl)-.alpha.,.alpha.,.alpha.-trifluoro-2,6-dinitro-p-toluidine
p-toluidine, n-(2-chloroethyl)-2,6-dinitro-n-propyl-.alpha.,.alpha.,.alpha.-trifluoro-
p-toluidine, n-(2-chloroethyl)-.alpha.,.alpha.,.alpha.-trifluoro-2,6-dinitro-n-propyl-
fluchloralin, pestanal(r), analytical standard
J-019109
Q15632819

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"For the successful approval and clinical prescription of insulin biosimilars, it is essential to show pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to the respective reference products sourced from the European Union and the United States."( Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins.
Andersen, G; Chen, W; Gan, Z; Hao, C; He, A; Heise, T; Li, L; Lu, J; Plum-Mörschel, L; Xie, T; Zijlstra, E, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency54.48270.000221.22318,912.5098AID1259243
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency43.27710.001022.650876.6163AID1224839
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency57.80670.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency54.94100.000817.505159.3239AID1159527
pregnane X nuclear receptorHomo sapiens (human)Potency21.68990.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.94100.000229.305416,493.5996AID743069
thyroid stimulating hormone receptorHomo sapiens (human)Potency2.33190.001628.015177.1139AID1224843; AID1224895
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID522815Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522805Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522814Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522813Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522809Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522819Antimicrobial activity against Cryptosporidium parvum by short-term in vitro culture assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522807Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522812Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522810Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522816Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522806Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522808Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522811Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (23.53)18.7374
1990's3 (17.65)18.2507
2000's4 (23.53)29.6817
2010's3 (17.65)24.3611
2020's3 (17.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.80 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index61.56 (26.88)
Search Engine Supply Index2.44 (0.95)

This Compound (38.80)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (10.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]